 |
|
  |
|
 |
PRESS RELEASES |
 |
|
|
= Add Release to Briefcase |
| All Releases |
 |
Savient Pharmaceuticals Appoints David Y. Norton Interim Chief Executive Officer
02-01-12
|
16.5 KB
|
| |
EAST BRUNSWICK, N.J., Feb. 1, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Company's Board of Directors has appointed David Y. Norton, a member of the Savient Board and former Company Group Chairman, Global Pharmaceuticals for Johnson & Johnson, to the role of Interim Chief Executive Officer, effective...
|
|
 |
Savient Pharmaceuticals Appoints Experienced Pharmaceutical Executive, David Veitch as President of Savient Europe
01-13-12
|
13.3 KB
|
| |
EAST BRUNSWICK, N.J., Jan. 13, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the appointment of David Veitch as President of Savient Europe, effective January 16, 2012. Mr. Veitch brings extensive commercial knowledge of the European Union across marketing, sales, market access and general management and has ove...
|
|
 |
Savient Pharmaceuticals Announces Permanent J-Code Assigned for KRYSTEXXA®
01-06-12
|
16.2 KB
|
| |
EAST BRUNSWICK, N.J., Jan. 6, 2012 /PRNewswire/ --Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that a product-specific billing code, or permanent J-code, for KRYSTEXXA® (pegloticase) became available on January 1, 2012. The new J-code, J2507, was assigned by the Centers for Medicare and Medicaid Services (CMS) and will help sim...
|
|
 |
Savient Pharmaceuticals to Present at the Noble Financial Capital Markets Eighth Annual Equity Conference
01-05-12
|
8.8 KB
|
| |
EAST BRUNSWICK, N.J., Jan. 5, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Kenneth Zuerblis, Executive Vice President and Chief Financial Officer of Savient will present at the Noble Financial Capital Markets Eighth Annual Equity Conference on Tuesday, January 17, 2012 at 10:00 AM Eastern Time. The confere...
|
|
 |
Savient Pharmaceuticals to Present at the 30th Annual J.P. Morgan Healthcare Conference
12-20-11
|
8.7 KB
|
| |
EAST BRUNSWICK, N.J., Dec. 20, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that John H. Johnson, Chief Executive Officer and President of Savient will present at the 30th Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2012 at 10:30 AM Pacific Time. The conference will be held at the Westin ...
|
|
 |
Savient Pharmaceuticals and Jim Belushi Launch "Check Out Your Gout" Educational Campaign
11-07-11
|
14.4 KB
|
| |
EAST BRUNSWICK, N.J., Nov. 7, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) and Jim Belushi today announced the launch of a new educational campaign, "Check Out Your Gout," to raise awareness about gout and a severe form of the condition known as refractory chronic gout, or RCG. As an actor, singer and performer, Belushi's roles...
|
|
 |
Savient Pharmaceuticals Announces New Data Surrounding KRYSTEXXA® and the Impact of Refractory Chronic Gout at the American College of Rheumatology Meeting
11-05-11
|
22.5 KB
|
| |
EAST BRUNSWICK, N.J., Nov. 5, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that data providing further clarity and context surrounding the risk for and management of infusion reactions that may occur with KRYSTEXXA® (pegloticase) in the treatment of refractory chronic gout (RCG) patients will be presented a...
|
|
 |
Savient Pharmaceuticals Receives J-code for KRYSTEXXA®
11-03-11
|
12.7 KB
|
| |
EAST BRUNSWICK, N.J., Nov. 3, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Centers for Medicare and Medicaid Services (CMS) has assigned a product-specific billing code, or J-code, for KRYSTEXXA® (pegloticase), which is used for the treatment of chronic gout in adult patients refractory to conventi...
|
|
 |
Savient Pharmaceuticals Reports Third Quarter 2011 Financial Results
11-03-11
|
22.1 KB
|
| |
EAST BRUNSWICK, N.J., Nov. 3, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three and nine months ended September 30, 2011, which reflect the Company's continuing investment in the U.S. launch of KRYSTEXXA® (pegloticase). Savient ended the quarter with $202.7 million in cash and shor...
|
|
 |
Savient Pharmaceuticals to Hold Third Quarter 2011 Financial Results Conference Call on Thursday, November 3, 2011
10-12-11
|
9.3 KB
|
| |
EAST BRUNSWICK, N.J., Oct. 12, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the company will release financial results for the third quarter 2011 prior to the open of the market on Thursday, November 3, 2011.
John H. Johnson, Chief Executive Officer and President, and Kenneth J. Zuerblis, Executive Vice...
|
|
 |
Savient Pharmaceuticals to Present at the Sixth Annual JMP Securities Healthcare Conference
09-13-11
|
8.7 KB
|
| |
EAST BRUNSWICK, N.J., Sept. 13, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer and President of Savient will present at the Sixth Annual JMP Securities Healthcare Conference on Wednesday, September 28, 2011 at 9:30 a.m. Eastern Time. The conference will be held at the...
|
|
 |
Savient Pharmaceuticals Names Kenneth J. Zuerblis Chief Financial Officer
09-12-11
|
13.0 KB
|
| |
EAST BRUNSWICK, N.J., Sept. 12, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the appointment of Kenneth J. Zuerblis as Executive Vice President & Chief Financial Officer, effective today. Mr. Zuerblis brings over 30 years of financial and operational experience to Savient and will be responsible for all financi...
|
|
 |
Savient Announces the Election of William F. Owen, Jr., M.D. and David Y. Norton to its Board of Directors
09-06-11
|
11.9 KB
|
| |
EAST BRUNSWICK, N.J., Sept. 6, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that William F. Owen, Jr., M.D. and David Y. Norton have been elected to the Company's Board of Directors, effective September 1, 2011. "We believe that Bill and David bring unique and relevant experience to our board of directors that w...
|
|
 |
Savient Pharmaceuticals Announces Publication of Pivotal Phase III KRYSTEXXA® Data in JAMA Demonstrating Significant Benefits in Refractory Chronic Gout Patients
08-16-11
|
19.5 KB
|
| |
EAST BRUNSWICK, N.J., Aug. 16, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that results from two pivotal KRYSTEXXA® (pegloticase) Phase III clinical studies in patients with refractory chronic gout (RCG) have been published in The Journal of the American Medical Association (JAMA). The data demonstrated th...
|
|
 |
Savient Pharmaceuticals to Present at the Wedbush Securities 2011 Life Sciences Management Access Conference
08-10-11
|
8.0 KB
|
| |
EAST BRUNSWICK, N.J., Aug. 10, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that John H. Johnson, Chief Executive Officer and President of Savient will present at the Wedbush Securities 2011 Life Sciences Management Access Conference on Tuesday, August 16, 2011, at 4:10 p.m. Eastern Time. The conference will be...
|
|
 |
Savient Pharmaceuticals Reports Second Quarter 2011 Financial Results
08-04-11
|
24.0 KB
|
| |
EAST BRUNSWICK, N.J., Aug. 4, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three and six months ended June 30, 2011, which are reflective of significant investments in the U.S. launch of KRYSTEXXA® (pegloticase). Savient ended the quarter with $240.3 million in cash and short-term ...
|
|
 |
Savient Pharmaceuticals Names Rheumatology Veteran Kenneth M. Bahrt, M.D. Chief Medical Officer
07-27-11
|
12.2 KB
|
| |
EAST BRUNSWICK, N.J., July 27, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced the appointment of Dr. Kenneth M. Bahrt as Chief Medical Officer, effective August 1, 2011. Dr. Bahrt, a Board Certified Rheumatologist, brings to Savient over 25 years of global medical affairs, drug safety and clinical practice, resea...
|
|
 |
Savient Pharmaceuticals to Hold Second Quarter 2011 Financial Results Conference Call on Thursday, August 4, 2011
07-20-11
|
8.4 KB
|
| |
EAST BRUNSWICK, N.J., July 20, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) announced today that the Company will release financial results for the second quarter 2011 prior to the open of the market on Thursday, August 4, 2011.
John H. Johnson, Chief Executive Officer and President, and David Gionco, Group Vice President a...
|
|
 |
Savient Pharmaceuticals Marketing Authorization Application for KRYSTEXXA® Accepted for Review by European Medicines Agency
05-26-11
|
11.5 KB
|
| |
EAST BRUNSWICK, N.J., May 26, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (Nasdaq: SVNT) today announced that the Marketing Authorization Application (MAA), filed by its wholly owned subsidiary, Savient Pharma Ireland Limited, seeking approval of KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to ...
|
|
 |
Savient Pharmaceuticals Reports First Quarter 2011 Financial Results
05-05-11
|
21.5 KB
|
| |
EAST BRUNSWICK, N.J., May 5, 2011 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today reported financial results for the three months ended March 31, 2011. Savient ended the quarter with $268.0 million in cash and short-term investments, an increase of $203.1 million since December 31, 2010, primarily due to the issuance and sale of...
|
|
|
|
|
Savient Pharmaceuticals, Inc. (the "Company") believes that the information included in the Investor Relations section of this website was correct at the time it was added to the website. However, the Company expressly disclaims any duty to update the information on the website and makes no representation or warranty as to accuracy and completeness of the contents of this Investor Relations section of the website or any other section of the website. Access to and use of the information on this website is at the user's own risk. The Company assumes no responsibility for any errors or omissions in the content of this website and disclaims any liability for damages of any kind (whether direct, consequential or punitive) arising out of the use of this website or the information contained on the website or on links to or from this website.
The statements contained in this website contain forward-looking statements within the meaning of the federal securities laws. All statements other than statements of historical facts included in the website are forward-looking statements that are subject to certain risks, trends and uncertainties that could cause actual results and achievements to differ materially from those expressed in such statements. These risks, trends and uncertainties are in some instances beyond our control. Words such as "anticipate," "believe," "estimate," "expect," "intend," "plan," "will" and other similar expressions identify forward-looking statements, although not all forward-looking statements contain these identifying words. In particular, any statements regarding our view of the refractory chronic gout (RCG) market size based on the completion of our recent comprehensive market research study, the status of our KRYSTEXXA® marketing efforts in the United States and additional plans related thereto, market demand and reimbursement for KRYSTEXXA in the United States, our preparations for and the timing of our market expansion plans, including regulatory submissions and potential marketing approvals for KRYSTEXXA in jurisdictions outside of the United States, including the European Union, the clinical benefits of KRYSTEXXA and our investigation of the expansion of the clinical utility of KRYSTEXXA, the likelihood of our being able to identify an appropriate strategic licensing or co-promotion transaction in certain territories, our work with secondary supply sources, and related matters are forward-looking statements. These forward-looking statements involve substantial risks and uncertainties and are based on our assessment and interpretation of the currently available data and information, current expectations, assumptions, estimates and projections about our business and the biopharmaceutical and specialty pharmaceutical industries in which we operate. Important factors that may affect our ability to achieve the matters addressed in these forward-looking statements include, but are not limited to, the actual market size for KRYSTEXXA, our ability to commercialize and gain market acceptance for KRYSTEXXA, market demand for KRYSTEXXA and market acceptance of reimbursement risks with third-party payers, risks associated with stringent government regulation of the biopharmaceutical industry, and in particular the approval of regulatory submissions and marketing approvals, the efficacy of KRYSTEXXA and our ability to expand its clinical utility, whether we are able to identify an appropriate strategic licensing or co-promotion transaction, our reliance on secondary supply sources to manufacture, market and distribute our products; and other important factors set forth more fully in our reports filed with the Securities and Exchange Commission, to which investors are referred for further information. We may not actually achieve the plans, intentions or expectations disclosed in our forward-looking statements, and you should not place undue reliance on our forward-looking statements, which speak only as of the date of publication of this website to shareholders. Actual results or events could differ materially from the plans, intentions and expectations disclosed in the forward-looking statements that we make. Our forward-looking statements do not reflect the potential impact of any future acquisitions, mergers, dispositions, joint ventures or investments that we may make.
|
  |
 |
Copyright © 2012 Savient Pharmaceuticals, Inc. All rights reserved. |
|
 |